| Rank | Clinic Name | Patient Rating | Country | Lead Doctor | experience | Techniques | Best For | Why It’s Ranked | Accreditations |
|---|---|---|---|---|---|---|---|---|---|
| #1 | 3.0 / 5 (1) | Beijing, China | 31+ years | CD7-directed CAR-T cell therapy, CAR-T plus local radiotherapy | — | 2,782 patients enrolled in CAR-T trials. 27 studies presented at EBMT. Multiple CAR-T programs: CD7-directed, myeloma, with radiotherapy. Hematologist with 900+ treatments. | — | ||
| #2 | — / 5 | Shanghai, China | 26+ years | CAR T-cell therapy, CAR-NK therapy, epigenetic immunotherapy | High-risk or refractory lymphoma cases | 87.5% complete remission at 3 months for lymphoma. 1,500+ CAR-T infusions performed since 2014. Multidisciplinary tumor board manages each case. | — | ||
| #3 | — / 5 | Qionghai, China | 20+ years | CAR T-cell therapy, CT (computer tomography) | — | — | — | ||
| #4 | 4.6 / 5 (19) | Guangzhou, China | 30+ years | EGFR-CAR T cell therapy, irreversible electroporation combined with CAR-T cell immunotherapy | Patients whose prior treatment courses were ineffective | JCI-accredited cancer hospital in Guangzhou with 30,000+ patients from 100 countries. Its CAR T-cell program is led by the hospital president, a clinical oncologist. | — | ||
| #5 | 4.5 / 5 | Chengdu, China | 35+ years | Tumor Marker Blood Test, Online Consultation with Oncologist | — | — | — |